4 completed, 1 recruiting, 1 unknown, 1 withdrawn. 6 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 3, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Recruiting 1 |
Follow domatinostat: new trials by email Literature Review of domatinostat trials Research Report on domatinostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Domatinostat With Sirolimus for Relapsed, Refractory Sarcoma and Osteosarcoma Domatinostat, Sirolimus - Sarcoma, Osteosarcoma | Phase 1 / Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 74 | 2026-07-15 | 2026-09-03 |
| Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1) domatinostat in combination with avelumab - Merkel Cell Carcinoma | Phase 2 | Withdrawn | 4SC AG | 2021-11-01 | 2021-11-18 | |
| Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1 domatinostat in combination with avelumab - Merkel Cell Carcinoma | Phase 2 | Completed | 4SC AG | 19 | 2020-10-13 | 2024-05-08 |
| Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma Domatinostat, Nivolumab, Ipilimumab - Malignant Melanoma Stage III | Phase 1 / Phase 2 | Completed | The Netherlands Cancer Institute | 44 | 2020-01-07 | 2025-03-10 |
| Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE) Domatinostat, Avelumab - Cancer, GI Cancer | Phase 2 | Unknown | Royal Marsden NHS Foundation Trust | 75 | 2019-01-11 | 2019-02-05 |
| 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy 4SC-202 in combination with Pembrolizumab - Malignant Melanoma | Phase 1 / Phase 2 | Completed | 4SC AG | 40 | 2017-09-25 | 2022-02-04 |
| Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) 4SC-202 - Advanced Hematologic Malignancies | Phase 1 | Completed | 4SC AG | 36 | 2011-03-01 | 2015-04-01 |
Carcinoma, Merkel Cell (2) · Melanoma (2) · Gastrointestinal Neoplasms (1) · Hematologic Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Osteosarcoma (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Sarcoma (1)
4SC AG (4) · H. Lee Moffitt Cancer Center and Research Institute (1) · Royal Marsden NHS Foundation Trust (1) · The Netherlands Cancer Institute (1)
Germany (3) · Italy (2) · Netherlands (2) · Australia (1) · Belgium (1) · France (1) · Spain (1) · United Kingdom (1) · United States (1)
Amy Armstrong, MD (1) · Andreas Engert, Prof. MD (1) · Christian Blank, Prof. (1) · David Cunningham (1) · Dirk Schadendorf, MD (1) · Jonathan Metts, MD (1)
2018 (1), 2019 (1)